Olema Oncology
Logotype for Olema Oncology Inc

Olema Oncology (OLMA) investor relations material

Olema Oncology Stifel 2026 Healthcare Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Olema Oncology Inc
Stifel 2026 Healthcare Conference 2026 summary11 Nov, 2026

OPERA clinical programs

  • OPERA-01, a 2L/3L monotherapy study, is expected to read out in Q1; the key test is whether phase II results replicate in phase III. Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in wild-type patients.

  • Palazestrant’s proposed differentiators include a 14-day half-life, higher exposure and complete ER antagonism; OPERA-01 separately analyzes ESR1-mutant and wild-type populations.

  • OPERA-02, a first-line study with KISQALI, is enrolling robustly. Enrollment excludes endocrine-resistant patients with less than 6 months’ response to prior endocrine therapy in advanced disease.

  • OPERA-02 enrollment may be expanded after review of SERENA-4 control-arm data at San Antonio in early December; added enrollment would modestly extend timing, while readout depends on event rate.

Combination data and pipeline

  • San Antonio presentations will include mature post-CDK4/6 everolimus-combination data with Kaplan-Meier PFS, tolerability and ESR1-mutant/wild-type analyses.

  • Atirmociclib combination enrollment is complete; initial tolerability and response-rate data will be presented in a mixed frontline/post-CDK4/6 population, without mature durability data.

  • The KAT6 inhibitor poster will update monotherapy and show initial breast-cancer fulvestrant-combination tolerability across multiple dose levels; dose selection remains ongoing.

  • Palazestrant plus KAT6 data are targeted for mid-2027; prostate-cancer enrollment with NUBEQA is expected to start in the near future, with data earliest by late 2027.

Commercial strategy and financing

  • Success in both OPERA-01 populations could support an oral endocrine option across a broader market; management cited a ~$5B opportunity, including $3B with no competition, versus ~$2B for ESR1-mutant disease.

  • U.S. launch preparations are underway, with a potential launch around mid-2028 contingent on a positive, fileable OPERA-01 readout; plans include U.S. and ex-U.S. filings and seeking collaborators for launch and ex-U.S. markets.

  • Cash was $414M at Q3 end, expected to support the launch window conditional on OPERA-01; management cited a favorable cash position and potential non-equity capital options.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Olema Oncology earnings date

Logotype for Olema Oncology Inc
UBS Global Biopharma Conference 202617 Nov, 2026
Olema Oncology
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Olema Oncology earnings date

Logotype for Olema Oncology Inc
UBS Global Biopharma Conference 202617 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Olema Pharmaceuticals, Inc., also known as Olema Oncology, is a clinical-stage biopharmaceutical company that focuses on developing targeted therapies for the treatment of women's cancers. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.